It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Drug Treatment Study For Patients With Social Anxiety Disorder

Clinical Trial Title: 
Randomized, double-blind, placebo-controlled study for investigating the efficacy of an investigational drug in subjects with social anxiety disorder (SAD) with or without comorbid major depressive disorder (MDD).
Clinical Trial Protocol ID: 
1503062
Clinical Trial Investigator Name: 
Joao V. Busnello, MD
Clinical Trial Protocol Description: 

The purpose of this study is to find out if an investigational drug reduces the symptoms of social anxiety disorder in subjects with SAD with or without comorbid MDD. During this 20-week study, participants will receive 12 weeks of treatment in which participants will either take the study medication or a placebo (an inactive pill). Throughout the study, participants’ symptoms will be assessed using questionnaires, interviews, and lab tests. Participants will also be asked to attend 7 to 28 day follow-up visit. All study-related procedures, psychiatric evaluation, medication, and transportation are free.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Be male or female outpatients, 18 to 64 years of age.
  • Have received a primary psychiatric diagnosis (designated by the patient as the most important source of current distress) of social anxiety disorder as defined by DSM-5 criteria.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Mental Health Disorders
Contact Phone: 
(312) 563-6687
Contact Name: 
Zerbrina Valdespino-Hayden